Analysis of drug-induced posterior reversible encephalopathy syndrome using the food and drug administration adverse drug events reporting system database

References

• Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500. doi: 10.1056/NEJM199602223340803
   PubMed Web of Science ®Google Scholar
• Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017;264(8):1608–1616. doi: 10.1007/s00415-016-8377-8
   PubMed Web of Science ®Google Scholar
• Cacho-Diaz B, Lorenzana-Mendoza NA, Salmeron-Moreno K, et al. Chemotherapy-induced posterior reversible encephalopathy syndrome: three case reports. Medicine (Baltimore). 2019;98(19):e15691. doi: 10.1097/MD.0000000000015691
   PubMed Web of Science ®Google Scholar
• Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.
   PubMed Web of Science ®Google Scholar
• Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–925. doi: 10.1016/S1474-4422(15)00111-8
   PubMed Web of Science ®Google Scholar
• Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427–432. doi: 10.4065/mcp.2009.0590
   PubMed Web of Science ®Google Scholar
• Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–417.
   Google Scholar
• Allen JA, Adlakha A, Bergethon P. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol. 2006;63(10):1475–1478. doi: 10.1001/archneur.63.10.1475
   PubMedGoogle Scholar
• Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology. 2007;68(23):2039–2040. doi: 10.1212/01.wnl.0000264428.76387.87
   PubMed Web of Science ®Google Scholar
• Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncology. 2007;12(11):1332–1335. doi: 10.1634/theoncologist.12-11-1332
   Google Scholar
• Kozak OS, Wijdicks EF, Manno EM, et al. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology. 2007;69(9):894–897. doi: 10.1212/01.wnl.0000269780.45472.16
   PubMed Web of Science ®Google Scholar
• Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM. 2012;105(1):69–75. doi: 10.1093/qjmed/hcr139
   PubMed Web of Science ®Google Scholar
• Junna MR, Rabinstein AA. Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. J Neurol Neurosurg Psychiatry. 2007;78(12):1410–1411. doi: 10.1136/jnnp.2007.121806
   PubMed Web of Science ®Google Scholar
• Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038–1048.
   PubMed Web of Science ®Google Scholar
• Rabinstein AA, Mandrekar J, Merrell R, et al. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis. 2012;21(4):254–258. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.011
   PubMed Web of Science ®Google Scholar
• Liman TG, Siebert E, Endres M. Posterior reversible encephalopathy syndrome. Curr Opin Neurol. 2019;32(1):25–35. doi: 10.1097/WCO.0000000000000640
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Bohm R, von Hehn L, Herdegen T, et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PloS One. 2016;11(6):e0157753.
   PubMed Web of Science ®Google Scholar
• http://www.meddramsso.com/index.asp
   Google Scholar
• Caster O, Aoki Y, Gattepaille LM, et al. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43(5):479–487. doi: 10.1007/s40264-020-00911-w
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Balcerac A, Bihan K, Psimaras D, et al. Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study. J Neurol. 2022;270(2):975–985. doi: 10.1007/s00415-022-11450-y
   PubMed Web of Science ®Google Scholar
• Ducros A, Fiedler U, Porcher R, et al. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke. 2010;41(11):2505–2511. doi: 10.1161/STROKEAHA.109.572313
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296–327. doi: 10.1097/01.Ccm.0000298158.12101.41
   PubMed Web of Science ®Google Scholar
• Baizabal-Carvallo JF, Barragán-Campos HM, Padilla-Aranda HJ, et al. Posterior reversible encephalopathy syndrome as a complication of acute lupus activity. Clin Neurol Neurosurg. 2009;111(4):359–363. doi: 10.1016/j.clineuro.2008.11.017
   PubMed Web of Science ®Google Scholar
• Tavares M, Arantes M, Chacim S, et al. Posterior reversible encephalopathy syndrome in children with hematologic malignancies. J Child Neurol. 2015;30(12):1669–1675. doi: 10.1177/0883073815578525
   PubMed Web of Science ®Google Scholar
• Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 2012;32(6):590–594. doi: 10.3747/pdi.2012.00152
   PubMed Web of Science ®Google Scholar
• Kaur G, Ashraf I, Peck MM, et al. Chemotherapy and immunosuppressant therapy-induced posterior reversible encephalopathy syndrome. Cureus. 2020;12(10):e11163. doi: 10.7759/cureus.11163
   PubMed Web of Science ®Google Scholar
• Melis M, Biagi C, Smabrekke L, et al. Drug-induced progressive Multifocal Leukoencephalopathy: a comprehensive analysis of the WHO adverse drug reaction database. CNS Drugs. 2015;29(10):879–891. doi: 10.1007/s40263-015-0286-3
   PubMed Web of Science ®Google Scholar
• Bhatt A, Farooq MU, Majid A, et al. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Clin Pract Neurol. 2009;5(3):163–169. doi: 10.1038/ncpneuro1045
   PubMedGoogle Scholar
• Chen YH, Huang CH. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine. Clin Breast Cancer. 2012;12(3):222–225. doi: 10.1016/j.clbc.2012.01.006
   PubMed Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–982. doi: 10.1056/NEJMc052954
   PubMed Web of Science ®Google Scholar
• How J, Blattner M, Fowler S, et al. Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature. Neurologist. 2016;21(6):112–117. doi: 10.1097/NRL.0000000000000105
   PubMed Web of Science ®Google Scholar
• Stjepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics. 2014;8:129–139. doi: 10.2147/BTT.S39381
   PubMedGoogle Scholar
• Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122(1):128–134. doi: 10.1046/j.1365-2141.2003.04447.x
   PubMed Web of Science ®Google Scholar
• Kamiya-Matsuoka C, Paker AM, Chi L, et al. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study. J Neurooncol. 2016;128(1):75–84. doi: 10.1007/s11060-016-2078-0
   PubMed Web of Science ®Google Scholar
• Hun M, Xie M, She Z, et al. Management and clinical outcome of posterior reversible encephalopathy syndrome in pediatric oncologic/hematologic diseases: a PRES subgroup analysis with a large sample size. Front Pediatr. 2021;9:678890. doi: 10.3389/fped.2021.678890
   PubMed Web of Science ®Google Scholar
• Anastasopoulou S, Eriksson MA, Heyman M, et al. Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: clinical characteristics, risk factors, course, and outcome of disease. Pediatr Blood Cancer. 2019;66(5):e27594. doi: 10.1002/pbc.27594
   PubMed Web of Science ®Google Scholar
• Zama D, Gasperini P, Berger M, et al. A survey on hematology-oncology pediatric AIEOP centres: the challenge of posterior reversible encephalopathy syndrome. Eur J Haematol. 2018;100(1):75–82. doi: 10.1111/ejh.12984
   PubMed Web of Science ®Google Scholar
• Gaziev J, Marziali S, Paciaroni K, et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with Hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(9):1531–1540. doi: 10.1016/j.bbmt.2017.05.033
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhao X, Fu HX, et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020;55(10):2035–2042. doi: 10.1038/s41409-020-0894-5
   PubMed Web of Science ®Google Scholar
• Thavamani A, Umapathi KK, Puliyel M, et al. Epidemiology, comorbidities, and outcomes of posterior reversible encephalopathy syndrome in children in the United States. Pediatr Neurol. 2020;103:21–26. doi: 10.1016/j.pediatrneurol.2019.07.007
   PubMed Web of Science ®Google Scholar
• Hafez HA, Ragab I, Sedky M, et al. Patterns, risk factors and outcome predictors of posterior reversible encephalopathy syndrome in pediatric cancer patients. Leuk Lymphoma. 2021;62(2):462–468. doi: 10.1080/10428194.2020.1832658
   PubMed Web of Science ®Google Scholar
• Li XY, Huang K, Zhou DH, et al. Severe hypertension is an independent risk factor for posterior reversible encephalopathy syndrome post-hematopoietic cell transplantation in children with thalassemia major. Clin Transplant. 2019;33(1):e13459. doi: 10.1111/ctr.13459
   PubMed Web of Science ®Google Scholar
• Danhofer P, Tomeckova M, Cerna D, et al. Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: a retrospective monocentric study. Seizure. 2019;72:1–10. doi: 10.1016/j.seizure.2019.08.007
   PubMed Web of Science ®Google Scholar
• Banerjee JS, Heyman M, Palomäki M, et al. Posterior reversible encephalopathy syndrome: risk factors and impact on the outcome in children with acute lymphoblastic leukemia treated with nordic protocols. J Pediatr Hematol Oncol. 2018;40(1):e13–e18. doi: 10.1097/MPH.0000000000001009
   PubMed Web of Science ®Google Scholar
• Tambasco N, Mastrodicasa E, Salvatori C, et al. Prognostic factors in children with PRES and hematologic diseases. Acta Neurol Scand. 2016;134(6):474–483. doi: 10.1111/ane.12570
   PubMed Web of Science ®Google Scholar
• Grossman A, Messerli FH, Grossman E. Drug induced hypertension – an unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763:15–22. doi: 10.1016/j.ejphar.2015.06.027
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125(1):14–22. doi: 10.1016/j.amjmed.2011.05.024
   PubMed Web of Science ®Google Scholar
• Dietrich J, Rao K, Pastorino S, et al. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233–242. doi: 10.1586/ecp.11.1
   PubMedGoogle Scholar
• Parikh NS, Schweitzer AD, Young RJ, et al. Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome. J Neurol Sci. 2017;380:11–15. doi: 10.1016/j.jns.2017.06.044
   PubMed Web of Science ®Google Scholar
• Bechstein WO, Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int. 2000;13(5):313–326. doi: 10.1007/s001470050708
   PubMed Web of Science ®Google Scholar
• Gijtenbeek JM, Bent M, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246(5):339–346. doi: 10.1007/s004150050360
   PubMed Web of Science ®Google Scholar
• Panda T, Aggarwal M, Naranje P, et al. Antithymocyte globulin-induced atypical haemorrhagic posterior reversible encephalopathy syndrome in severe aplastic anaemia. BMJ Case Rep. 2021;14(7):e244427. doi: 10.1136/bcr-2021-244427
   PubMedGoogle Scholar
• Dayama A, Seth T, Mishra P, et al. Antithymocyte globulin induced posterior reversible encephalopathy in aplastic anemia. Neurol India. 2013;61(4):430–431. doi: 10.4103/0028-3886.117594
   PubMed Web of Science ®Google Scholar